RxDoctor Payments Data

Roberto Fernandez Blay, MD

Internal Medicine · Hollywood, FLNPI 1205821352

Payments from drug & device makers

$650in general payments, 2019–2025

Across 26 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$175
  • Merz North America, Inc.$122
  • Gilead$84
  • Kvk-tech, Inc.$67
  • Johnson & Johnson$35
  • Novartis$34
  • plus $132 from 6 others

What the payments were for

  • Food & beverage$63598%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$650 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$7,058
Medicare patients
14
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$24,595
OzempicSemaglutide22$20,418
EliquisApixaban30$19,690
NuedextaDextromethorphan Hbr/Quinidine11$16,451
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$6,595
LantusInsulin Glargine,hum.Rec.Anlog32$2,147
Wixela InhubFluticasone Propion/Salmeterol13$1,584
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide80$1,539
Levothyroxine Sodium138$1,496
Rosuvastatin Calcium144$1,226
Lacosamide17$1,138
Metoprolol Succinate118$1,136
Losartan Potassium151$1,045
Atorvastatin Calcium136$1,038
Metformin Hcl257$889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$30$24,59524 claims
PfizerEliquis$32$19,69030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →